Oracle stock drops even as tech rises after Saudi healthcare cloud deal
27 January 2026
1 min read

Oracle stock drops even as tech rises after Saudi healthcare cloud deal

New York, Jan 27, 2026, 10:55 AM EST — Regular session

  • Oracle shares dropped roughly 3% in morning trading, trailing behind gains in the broader tech sector
  • Saudi healthcare group Alrajhi Medicine will implement Oracle Health and Fusion Cloud apps, the company announced
  • Traders are eyeing March results for clues on cloud demand and spending trends

Oracle Corp shares slipped on Tuesday, erasing some of Monday’s gains, despite a rally in major U.S. tech stocks and the Nasdaq-focused QQQ. In morning trading, Oracle dropped roughly 3.3% to $176.35.

This matters because Oracle’s shares have been tossed around amid doubts about how fast its cloud and AI investments will translate into consistent profits, and how much cash it needs to expand capacity. Investors have reacted sharply to any hint that spending is outpacing returns. 1

Early Tuesday, Oracle announced that Alrajhi Medicine, a private healthcare network in Saudi Arabia, will adopt Oracle Health Foundation’s electronic health record software — a digital system for patient records — along with Oracle Fusion Cloud Applications. Oracle said this integration will link clinical and business operations. 2

“We are transforming our digital operations by deploying Oracle’s next-generation clinical and enterprise solutions,” said Omar Turjman, chief information officer at Alrajhi Medicine. Seema Verma, Oracle Health’s executive vice president, noted that Oracle’s offerings “uniquely align” with the group’s goal to modernize healthcare systems. 2

The announcement comes as Oracle continues to highlight its physical expansion to meet AI demand. In a blog post Monday, the company revealed ongoing AI infrastructure projects “in partnership with OpenAI” across Texas, New Mexico, Wisconsin, and Michigan. It also noted investments in power upgrades at those sites. 3

Oracle’s shares swung between $174.84 and $185.88 on Tuesday, following a roughly 3% gain the day before, when the stock closed at $182.44. 4

Oracle slipped behind its rivals in early trading, while Microsoft climbed around 1.6% and Amazon gained roughly 1.5%. The S&P 500-tracking SPY edged up about 0.4%.

In a separate SEC filing Monday, Oracle’s chief legal officer, Stuart Levey, disclosed an award related to dividend equivalents on previously issued restricted stock units. 5

Tuesday’s sell-off highlighted the lingering risks around Oracle: its aggressive AI push demands significant investment, and the market shows little tolerance for missed forecasts or rising expenses. Shares took a steep hit in December after earnings fell short and investors fixated on spending projections, Reuters reported. 1

Traders are now eyeing Oracle’s upcoming quarterly report, expected March 9. Investors will be watching closely for updates on cloud demand, capacity expansions, and the company’s funding strategy. 6

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Natural gas price drops after winter-storm spike as contract roll hits; UNG and EQT slip
Previous Story

Natural gas price drops after winter-storm spike as contract roll hits; UNG and EQT slip

First Majestic Silver stock dips as silver whipsaws near records, retail ETF rush in focus
Next Story

First Majestic Silver stock dips as silver whipsaws near records, retail ETF rush in focus

Go toTop